Kung, Wei-Wei
Ramachandran, Sarath
Makukhin, Nikolai
Bruno, Elvira
Ciulli, Alessio http://orcid.org/0000-0002-8654-1670
Article History
Received: 10 December 2018
Accepted: 26 April 2019
First Online: 10 June 2019
Competing interests
: The A.C. laboratory receives sponsored research support from Boehringer Ingelheim and Nurix, Inc. A.C. is a scientific founder, director and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The remaining authors declare no competing interests.